In conclusion, glioblastoma is the most common primary malignant brain tumor affecting approximately seven new patients out of every hundred thousand in the population. The tumor is first identified on imaging and then tissue diagnosis is obtained either through a needle biopsy or as part of surgical resection. The current standard of care treatment involves maximal safe resection followed by radiation and chemotherapy with the option of tumor treating electromagnetic fields. However, even with the current standard of care therapy, most patients don’t live beyond two years. Our understanding of glioblastoma on a molecular genetic level is advancing rapidly and has already yielded several clinical trials and advancements in treatment, including in the field of immunotherapy. Patients should feel justified in seeking care at high volume comprehensive brain tumor centers prior to initiating surgery or other treatment.